Agenda

 

 

                                                                               National Cancer Institute (NCI)
                                                Mechanisms of Cancer Drug Resistance and Sensitivity Symposium
                                                                                         October 4-5, 2018

                                                          Shady Grove Campus: 9609 Medical Center Drive, Rockville, MD 20850
                                                                                                         Room 406/408/410

 

                                                                                        DRAFT AGENDA

Thursday, Oct 4 Friday, Oct 5

Thursday, October 4, 2018

Day 1: Thursday, October 4th; 1:00 p.m. – 5:35 p.m. ET

01:00 pm - 01:05 pm EST
Welcome

L. Austin Doyle, MD (NCI)

01:05 pm - 01:15 pm EST
Goals of Symposium

James Doroshow, MD (NCI)

01:15 pm - 01:20 pm EST
Introduction of Keynote Speaker

Charles Sawyers, MD (MSK; U54 DRSN)

01:20 pm - 01:50 pm EST
Keynote Presentation – Discovery of targetable mechanisms of endocrine resistance in ER+, HER2-negative breast cancer

Carlos Arteaga, MD (UT Southwestern)

01:50 pm - 02:00 pm EST

Q & A

Session 1: Insights into Immunomodulatory Drug Resistance

02:00 pm - 02:10 pm EST
Introduction

Helen Chen, MD (NCI)

02:10 pm - 02:30 pm EST
Organoid modeling of the tumor immune microenvironment

Calvin Kuo, MD, PhD (Stanford; U54 DRSN)

02:30 pm - 02:50 pm EST
Defining T cell states associated with response to checkpoint immunotherapy in melanoma

Moshe Sade-Feldman, PhD (MGH; U54 DRSN)

02:50 pm - 03:10 pm EST
Genetic mechanisms of sensitivity and resistance to cancer immunotherapy

Drew Pardoll, MD, PhD (JHMI)

03:10 pm - 03:30 pm EST
Unraveling the intrinsic and extrinsic resistance mechanisms to checkpoint blockade

Siwen Hu-Lieskovan, MD, PhD (UCLA)

03:30 pm - 03:50 pm EST

Panel Discussion 

03:50 pm - 04:05 pm EST

Coffee Break

Session 2: The Tumor Microenvironment in Drug Resistance and Sensitivity

04:05 pm - 04:15 pm EST
Introduction

Trever Bivona, MD, PhD (UCSF; U54 DRSN)

04:15 pm - 04:35 pm EST
Cancer Treatment Resistance Mediated by Damage Responses in the Tumor Microenvironment

Pete Nelson, MD (Fred Hutch/UW: U54 DRSN)

04:35 pm - 04:55 pm EST
Tumor microenvironmental changes induced by TKI treatment in advanced NSCLC

Collin Blakely, MD, PhD (UCSF; U54 DRSN)

04:55 pm - 05:15 pm EST
Tumor intrinsic and microenvironmental mechanisms driving drug combination efficacy and resistance in AML

Jeffrey Tyner, PhD (OHSU; U54 DRSN)

05:15 pm - 05:35 pm EST

Panel Discussion

Friday, October 5, 2018

Day 2: Friday, October 5th; 8:00 a.m. – 5:15 p.m. ET

08:00 am - 08:15 am EST
NCI Initiatives to Fund Current and Future Drug Resistance & Sensitivity Research

L. Austin Doyle, MD (NCI)

08:15 am - 08:20 am EST
Introduction of Keynote Speaker

L. Austin Doyle, MD (NCI)

08:20 am - 08:50 am EST
Keynote Presentation: Lineage Plasticity in Cancer -

Charles Sawyers, MD (MSK; U54 DRSN)

08:50 am - 09:00 am EST

Q & A

Session 3: Emerging Pre-clinical Models to study Drug Resistance and Sensitivity

09:00 am - 09:10 am EST
Introduction

Keith Stewart, MB, ChB (Mayo Clinic Arizona; U54 DRSN)

09:10 am - 09:30 am EST
Utilizing preclinical in vivo models to elucidate mechanisms of drug resistance

Juliet Williams, PhD (Novartis)

09:30 am - 09:50 am EST
A systematic liquid biopsy platform to study drug resistance

Ryan Corcoran, MD, PhD (MGH; U54 DRSN)

09:50 am - 10:10 am EST
3D models versus 2D exponentially growing models: Are they more “in vivo” like?

Beverly Teicher Ph.D., (FLNRC, NCI)

10:10 am - 10:30 am EST
Transcriptional regulation of prostate cancer lineage specification and antiandrogen sensitivity

Yu Chen, MD, PhD (MSK; U54 DRSN)

10:30 am - 10:50 am EST

Panel Discussion

10:50 am - 12:15 pm EST

Poster Session and Networking Break

12:15 pm - 01:00 pm EST

Lunch (on your own)

Session 4: Resistance Biomarkers and Pathways

01:00 pm - 01:10 pm EST
Introduction

Jeffrey Tyner, PhD (OHSU; U54 DSRN)

01:10 pm - 01:30 pm EST
Imaging stem cell signals in cancer heterogeneity and therapy resistance

Tannishtha Reya, PhD (UCSD)

01:30 pm - 01:50 pm EST
In vivo screens for enhancers of checkpoint blockage response

Nick Haining, BCh, BM (DFCI)

01:50 pm - 02:10 pm EST
Identification of genetic alterations associated with poor treatment response in DLBCL patients treated with lenalidomide/RCHOP

Thomas Witzig, MD (Mayo Clinic Minnesota)

02:10 pm - 02:30 pm EST
Non-genomic mechanisms of resistance to drugs targeting oncogenic drivers in lung cancer

Christine Lovly, MD, PhD (Vanderbilt)

02:30 pm - 02:50 pm EST

Panel Discussion

02:50 pm - 03:30 pm EST

Networking Break

Session 5: Large Dataset Analysis in Drug Resistance Research

03:30 pm - 03:40 pm EST
Introduction

Pete Nelson, MD (Fred Hutch/UW: U54 DRSN)

03:40 pm - 04:00 pm EST
Data integration and functional interrogation to overcome drug resistance

Kris Wood, PhD (Duke)

04:00 pm - 04:20 pm EST
Integrative analysis to identify resistance biomarkers

Eliezer Van Allen, MD (Harvard/DFCI)

04:20 pm - 04:40 pm EST
Genome-wide screens in AML

Shannon McWeeney, PhD (OHSU; U54 DRSN)

04:40 pm - 05:00 pm EST

Panel Discussion

05:00 pm - 05:15 pm EST
Wrap-up

Jeff Moscow, MD (NCI)